LiDCO, the UK-based, AIM-traded cardiovascular monitoring company, announces its Preliminary Results for the 12 months ended 31 January 2006.

Group performance shows over 50% sales growth, with operating losses and cash outflow almost halved.

Dr Terry O’Brien, Chief Executive, stated: “I am delighted we are able to report over 50% sales growth in both monitors and sensors, since it is the combination of both these achievements that is taking LiDCO towards its goal of becoming the pre-eminent minimally invasive technology for hemodynamic monitoring.”

Financial Highlights

N.B. Since the previous reported period was 13 months, all comparatives have been adjusted onto a 12 months equivalent basis – see table on next page.

• Turnover at £3.4m, up 51%
  
  
• Gross profit up 68% at £2.6m
  
  
• Gross profit margin increased from 67% to 75%
  
  
• Administrative expenses down by 16% at £4.6m
  
• Pre-tax operating loss down 47% at £2.1m
  
  
• Loss per share reduced by 55% at 1.9p
  
  
• Cash outflow before financing down 38% at £2.2m

The full results are available to download in PDF format.

For more information please contact: